CIRM's New Chair to Sell Stem Cell Stocks Shortly but Continue Link with Bond Firm
The new chairman of the $3 billion California stem cell agency, Jonathan Thomas, says he will soon sell his interests in a California stem cell company but will retain his financial ties to a bond investment firm, pending a double-check with the agency's outside counsel.
As part of his pitch for the $400,000 post as the chair of CIRM, Thomas, a bond fin…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.